Case Report and literature review: immune checkpoint inhibitor-associated myasthenia gravis and myocarditis
Frontiers in Cardiovascular Medicine · 19.03.2026 · 13
DOI: 10.3389/fcvm.2026.1764567 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 19.03.2026. Verfasst von Zhiyue Shang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Cardiovascular Hospital Affiliated to Shanxi Medical University; Shanxi Key Laboratory of Heart Failure Precision Medicine, …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
To investigate the clinical features of immune checkpoint inhibitor (ICI)-associated myasthenia gravis (MG) with concurrent myocarditis with the aim of enhancing our understanding. We retrospectively analyzed the clinical data of a patient diagnosed with ICI-associated MG and myocarditis, and reviewed the relevant literature. A 67-year-old man was admitted with a 4-day history of right-sided ptosis and blurred vision. His medical history included resection of adenocarcinoma in the right upper lung lobe over 18 years ago and a diagnosis of new lung cancer in the right lower lobe four months prior to presentation. In May 2025, lung cancer recurrence was identified but the patient declined any treatment at that time. In September 2025, following radiotherapy and a single dose of serplulimab (a programmed cell death protein 1 inhibitor, PD-1), the patient developed clinical symptoms including ptosis, a positive fatigue test, and a positive neostigmine test, suggestive of myasthenia gravis. Biochemical tests, electrocardiogram (ECG), and echocardiography indicated myocarditis. The clinical diagnosis was ICI-associated myocarditis. Management involved the discontinuation of immunotherapy, administration of glucocorticoids, and symptomatic supportive treatment, which led to clinical improvement. A literature review summarized 45 cases, indicating that this overlapping immune-related adverse event is rare and has a poor prognosis. Multiple adverse reactions to ICIs can occur simultaneously. Prompt recognition of symptoms and initiation of targeted and effective treatments are crucial for optimizing clinical outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Cardiovascular Hospital Affiliated to Shanxi Medical University; Shanxi Key Laboratory of Heart Failure Precision Medicine, Taiyuan, Shanxi, China.
- Department of Pharmacy, Cardiovascular Hospital Affiliated to Shanxi Medical University; Shanxi Key Laboratory of Heart Failure Precision Medicine, Taiyuan, Shanxi, China.
Zitieren
APA
Shang, Z., Hao, S., Wang, J., & Li, W. (2026). Case Report and literature review: immune checkpoint inhibitor-associated myasthenia gravis and myocarditis. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1764567
Vancouver
Shang Z, Hao S, Wang J, Li W. Case Report and literature review: immune checkpoint inhibitor-associated myasthenia gravis and myocarditis. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1764567
BibTeX
@article{Shang2026,
author = {Shang, Zhiyue and Hao, Shuai and Wang, Jianhong and Li, Weirong},
title = {Case Report and literature review: immune checkpoint inhibitor-associated myasthenia gravis and myocarditis},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1764567}
}
EUVIMED